ICCC
ICCC
NASDAQ · Biotechnology

Immucell Corp

$10.52
+0.30 (+2.94%)
Financial Highlights (FY 2026)
Revenue
27.76M
Net Income
-1,044,170
Gross Margin
41.4%
Profit Margin
-3.8%
Rev Growth
+14.2%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 41.4% 41.4% 49.1% 49.1%
Operating Margin -2.1% -1.9% 4.8% 4.7%
Profit Margin -3.8% -3.6% 4.8% 5.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 27.76M 24.31M 25.83M 25.29M
Gross Profit 11.49M 10.07M 12.69M 12.42M
Operating Income -594,069 -468,262 1.23M 1.19M
Net Income -1,044,170 -823,045 1.23M 1.32M
Gross Margin 41.4% 41.4% 49.1% 49.1%
Operating Margin -2.1% -1.9% 4.8% 4.7%
Profit Margin -3.8% -3.6% 4.8% 5.2%
Rev Growth +14.2% +14.2% +0.8% +23.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 11.37M 11.37M 3.09M 3.10M
Total Equity 33.81M 33.81M 31.72M 30.36M
D/E Ratio 0.34 0.34 0.10 0.10
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 2.13M 1.77M 1.46M 1.67M
Free Cash Flow — — 1.13M 847.0K